Arthritis Res Ther
|
Viewing options:Associated material:Related literature:- Articles citing this article
- Other articles by authors
- Related articles/pages
Tools:Post to:
|
ReviewDrugs in development: bisphosphonates and metalloproteinase inhibitorsJon B Catterall and Tim E Cawston  Department of Rheumatology, The Medical School, University of Newcastle upon Tyne, UK  author email corresponding author email
Arthritis Res Ther 2003,
5:12-24doi:10.1186/ar604
|
| Published: |
8 November 2002 |
Abstract
The destruction of bone and cartilage is characteristic of the progression of musculoskeletal diseases. The present review discusses the developments made with two different classes of drugs, the bisphosphonates and matrix metalloproteinase inhibitors. Bisphosphonates have proven to be an effective and safe treatment for the prevention of bone loss, especially in osteoporotic disease, and may have a role in the treatment of arthritic diseases. The development of matrix metalloproteinase inhibitors and their role as potential therapies are also discussed, especially in the light of the disappointing human trials data so far published. | 
on Google Scholar
